Zydus announced that the United States Food and Drug Administration (USFDA) has granted ‘Fast Track Designation’ to Saroglitazar Mg for the treatment of patients with primary biliary cholangitis (PBC). Fast Track is a process of the USFDA which expedites the review of drugs to treat serious conditions and fill an unmet medical need. A drug that receives Fast Track designation is eligible for Accelerated Approval and Priority Review if the relevant criteria are met. The purpose is to get important new drugs to the patients faster.
The global market for primary biliary cholangitis treatment is expected to grow at a CAGR of 36.3 per cent from 2018 – 2026 and is expected to reach $10.8 billion by 2026 as per Coherent market insights.
Saroglitazar Mg is a potent and selective peroxisome proliferator-activated receptor alpha and gamma dual agonist. Results of PHASE 2, prospective multicentre randomized double-blind, placebo-controlled study to evaluate the safety, tolerability and efficacy of Saroglitazar Mg in patients with PRIMARY BILIARY CHOLANGITIS (EPICS) was presented earlier at The Liver Meeting 2020, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) [ClinicalTrials.gov Identifier: NCT03112681]. The treatment options are still evolving for primary biliary cholangitis and Saroglitazar holds immense potential based on its safety and efficacy profile so far.
Speaking on the development, Pankaj R Patel, Chairman, Zydus Cadila said, “The awarding of Fast Track Designation to Saroglitazar, an investigational candidate for the treatment of PBC, is an important recognition by USFDA to address the serious condition and bridge an unmet medical need in the treatment of PBC patients. We are very thankful to the USFDA for their timely and useful feedback on the clinical trial designs of Saroglitazar Mg and will continue to work closely with the USFDA for Clinical Development for Saroglitazar Mg for patients with Primary Biliary Cholangitis (PBC).”